P-137 Phase 1/1b Study Evaluating KIN-3248, a Next-Generation, Irreversible Pan-Fgfr Inhibitor (fgfri), in Patients (pts) with Advanced Cholangiocarcinoma (CCA) and Other Solid Tumors Harboring FGFR2 And/or FGFR3 Gene Alterations
Annals of Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined